Goldman Sachs
NKTR icon

Goldman Sachs’s Nektar Therapeutics NKTR Stock Holding History

Goldman Sachs’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,833
Closed -$372K – 6802
2021
Q4 		$372K Buy
1,833
+333
+22% +$72.2K ﹤0.01% 5557
2021
Q3 		$404K Sell
1,500
-500
-25% -$120K ﹤0.01% 5327
2021
Q2 		$515K Buy
+2,000
New +$554K ﹤0.01% 5197
2018
Q4 		– Sell
-1,580
Closed -$1.45M – 5526
2018
Q3 		$1.45M Buy
+1,580
New +$1.35M ﹤0.01% 3813
2018
Q1 		– Sell
-2,593
Closed -$2.32M – 6232
2017
Q4 		$2.32M Sell
2,593
-74
-3% -$43.8K ﹤0.01% 3662
2017
Q3 		$960K Hold
2,667
– – ﹤0.01% 4608
2017
Q2 		$782K Buy
+2,667
New +$771K ﹤0.01% 4692
2016
Q1 		– Sell
-473
Closed -$120K – 7239
2015
Q4 		$120K Hold
473
– – ﹤0.01% 6072
2015
Q3 		$78K Sell
473
-2,654
-85% -$469K ﹤0.01% 6614
2015
Q2 		$587K Sell
3,127
-3,806
-55% -$655K ﹤0.01% 5020
2015
Q1 		$1.14M Buy
+6,933
New +$1.42M ﹤0.01% 4323
2014
Q3 		– Sell
-2,487
Closed -$478K – 7206
2014
Q2 		$478K Buy
+2,487
New +$440K ﹤0.01% 5365
2014
Q1 		– Sell
-3,333
Closed -$568K – 6870
2013
Q4 		$568K Buy
3,333
+200
+6% +$32.3K ﹤0.01% 5207
2013
Q3 		$491K Buy
+3,133
New +$579K ﹤0.01% 5161

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's NKTR Position: Q2 2026 in Review

Goldman Sachs increased its Nektar Therapeutics (NKTR) stake by 80% in Q2 2026, buying an estimated $7.43M and bringing the position to 228,490 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2855.

Goldman Sachs first reported a position in NKTR in Q2 2013 and has held it in 53 quarters since. The position peaked at $160M in Q1 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Goldman Sachs held 228,490 shares of Nektar Therapeutics worth $16M as of Q2 2026.
  • Goldman Sachs bought 101,548 Nektar Therapeutics shares in Q2 2026, an estimated $7.43M.
  • Nektar Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2855 holding.
  • Goldman Sachs first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's Nektar Therapeutics position peaked at $160M in Q1 2018.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.